AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases. They are currently focusing on CNS disorders, in particular Alzheimer’s Disease (AD). They target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).

Biotechnology

AltPep

Valerie Daggett

Amy C.

Jeff Posakony, Ph.D.

Jae Hyun Park

Calvin Fries

Nancy Hill

Gil Block

Patrik Edenholm

Charles Horne

The Leadership Team at AltPep Corporation guides the strategic direction and operational execution of the company’s mission to revolutionize the diagnosis and treatment of amyloid diseases. Comprised of top executives including the CEO, CFO, CMO, and other key leaders, this team drives innovation, ensures regulatory compliance, secures funding, and cultivates business partnerships to advance the development of their groundbreaking therapies for Alzheimer's Disease and other CNS disorders. Through collaboration and foresight, they strive to position AltPep as a leader in the biomedical field.

Leadership Team

Advisory Team

Business Operations Team

Leadership Team

About

Team members

Other teams at AltPep

Advisory Team

Business Operations Team